← Patent-cliff monitor small molecule LUMAKRAS SOTORASIB
Loss of exclusivity September 2040 latest FDA-listed patent expiry
Company Amgen → See this company's full patent-cliff portfolio Drug detail Brand name LUMAKRAS Active ingredient SOTORASIB Strength 120MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval May 2021 Marketing status RX
Listed patents Patent Expires Type 11426404 September 2040 use U-4107 12398133 May 2040 substance, product 11236091 May 2040 substance, product 11827635 May 2040 substance, product 12280056 November 2039 use U-4107 10519146 May 2038 substance, product
Regulatory exclusivity Code Expires ODE-507 January 2032 ODE-352 May 2028 I-962 January 2028 NCE May 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.